|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
(none)
|
|
INDICATIONS:
|
|
Deficiency, vitamin and mineral |
| |
|
|
SIDE EFFECTS:
|
|
Blurred vision |
|
diarrhea |
|
dizziness |
|
headache |
|
nausea or stomach cramps |
|
unusual tiredness or weakness |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Hypoprothrombinemia due to vitamin K deficiency |
|
|
ADULT DOSE:
|
|
Deficiency (prophylaxis)-
Oral, amount based on normal daily recommended intakes:
Persons U.S. Canada
mg Units mg Units
alpha-TE alpha-TE
Adolescent and adult 10 16.7 6-10 10-16.7
males
Adolescent and adult 8 13 5-7 8.3-11.7
females
Pregnant females 10 16.7 8-9 13-15
Breast-feeding 11-12 18-20 9-10 15-16.7
females
Deficiency (treatment)-
Treatment dose is individualized by prescriber based on severity of deficiency. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Deficiency (prophylaxis)-
Premature infants receiving formulas high in polyunsaturated fatty acids (PUFA)-Oral, 15 to 25 Units per day, or 7 Units per Liter of formula.
Infants with chronic cholestasis-Oral, 15 to 25 Units of a water-miscible preparation per kg of body weight per day.
Normal birthweight infants-Oral, 5 Units per Liter of formula.
Other children-Oral, amount based on normal daily recommended intakes:
Persons U.S. Canada
mg Units mg Units
alpha-TE alpha-TE
Infants and children 3-6 5-10 3-4 5-6.7
Birth to 3 years of age
4 to 6 years of age 7 11.7 5 8.3
7 to 10 years of age 7 11.7 6-8 10-13
Deficiency (treatment)-
Treatment dose is individualized by prescriber based on severity of deficiency. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|